

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 25, No 27

C O N T E N T S

September 20, 2007

Editorials

- **Prostate Cancer Quality of Life: Beyond Initial Treatment—and the Patient**
James A. Talcott (see article on page 4171) 4155
- **Ovarian Cancer: Is Dose Intensity Dead?**
Robert F. Ozols (see article on page 4187) 4157
- **How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above**
Richard G. Moore and Robert C. Bast Jr (see article on page 4194) 4159
- **Low-Dose Tamoxifen for Combination Hormone Replacement Therapy Users**
Carol J. Fabian (see article on page 4201) 4162
- **Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?**
Robert J. Mayer (see articles on pages 4217 and 4224) 4165

Comments and Controversies

- **Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action**
Maurie Markman 4168

Original Reports

GENITOURINARY CANCER

- **Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life**
Laurel L. Northouse, Darlene W. Mood, James E. Montie, Howard M. Sandler, Jeffrey D. Forman, Maha Hussain, Kenneth J. Pienta, David C. Smith, Martin G. Sanda, and Trace Kershaw
(see editorial on page 4155) 4171
- **Identification of Patients With Prostate Cancer Who Benefit From Immediate Postoperative Radiotherapy: EORTC 22911**
Theodorus H. Van der Kwast, Michel Bolla, Hein Van Poppel, Paul Van Cangh, Kris Vekemans, Luigi Da Pozzo, Jean-Francois Bosset, Karl H. Kurth, Fritz H. Schröder, and Laurence Collette 4178

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 330 John Carlyle St, Suite 300, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 330 John Carlyle St, Suite 300, Alexandria, VA 22314.

2007 annual subscription rates, effective September 1, 2006: United States and possessions: individual, \$487; single issue, \$35. International: individual, \$678; single issue, \$45. Institutions: Tier 1: \$670 US, \$950 Int'l; Tier 2: \$780 US, \$1,060 Int'l; Tier 3: \$1,130 US, \$1,410 Int'l; Tier 4: \$1,245 US; \$1,525 Int'l; Tier 5: contact *JCO* for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$240; all other countries, \$336. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. *JCO* Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

GYNECOLOGIC CANCER

- ① **Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT**

Volker Möbus, Hannes Wandt, Norbert Frickhofen, Carmelo Bengala, Kim Champion, Rainer Kimmig, Helmut Ostermann, Axel Hinke, and Jonathan A. Ledermann (see editorial on page 4157) 4187

- ① **Inclusion of CA-125 Does Not Improve Mathematical Models Developed to Distinguish Between Benign and Malignant Adnexal Tumors**

Dirk Timmerman, Ben Van Calster, Davor Jurkovic, Lil Valentin, Antonia C. Testa, Jean-Pierre Bernard, Caroline Van Holsbeke, Sabine Van Huffel, Ignace Vergote, and Tom Bourne (see editorial on page 4159) 4194

BREAST CANCER

- ① **Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users**

Andrea Decensi, Sara Gandini, Davide Serrano, Massimiliano Cazzaniga, Maria Pizzamiglio, Fausto Maffini, Giuseppe Pelosi, Cristina Daldoss, Umberto Omodei, Harriet Johansson, Debora Macis, Matteo Lazzeroni, Mauro Penotti, Laura Sironi, Simona Moroni, Vanda Bianco, Gabriella Rondanina, Jennifer Gjerde, Aliana Guerrieri-Gonzaga, and Bernardo Bonanni (see editorial on page 4162) 4201

- ① **Incidence and Prognosis of Synchronous and Metachronous Bilateral Breast Cancer**

Mikael Hartman, Kamila Czene, Marie Reilly, Jan Adolfsson, Jonas Bergh, Hans-Olov Adami, Paul W. Dickman, and Per Hall 4210

GASTROINTESTINAL CANCER

- ① **Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group**

Rainer Porschen, Hendrik-Tobias Arkenau, Stephan Kubicka, Richard Greil, Thomas Seufferlein, Werner Freier, Albrecht Kretzschmar, Ullrich Graeven, Axel Grothey, Axel Hinke, Wolff Schmiegel, and Hans-Joachim Schmoll (see editorial on page 4165 and article on page 4224) 4217

- ① **Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial**

Eduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Manuel Chaves, Alberto Abad, Alfredo Carrato, Bernardo Queralt, Juan José Reina, Joan Maurel, Encarnación González-Flores, Jorge Aparicio, Fernando Rivera, Ferrán Losa, and Enrique Aranda (see editorial on page 4165 and article on page 4217) 4224

- ① **Specific Clinical and Biological Features Characterize Inflammatory Bowel Disease–Associated Colorectal Cancers Showing Microsatellite Instability**

Magali Svrcek, Jamila El-Bchiri, Alexandra Chalastanis, Emilie Capel, Sylvie Dumont, Olivier Buhard, Carla Oliveira, Raquel Seruca, Céline Bossard, Jean-François Mosnier, Françoise Berger, Emmanuelle Leteurtre, Anne Lavergne-Slove, Marie-Pierre Chenard, Richard Hamelin, Jacques Cosnes, Laurent Beaugerie, Emmanuel Tiret, Alex Duval, and Jean-François Fléjou 4231

PEDIATRIC ONCOLOGY

- ① **Reduction of Health Status 7 Years After Addition of Chemotherapy to Craniospinal Irradiation for Medulloblastoma: A Follow-Up Study in PNET 3 Trial Survivors—on behalf of the CCLG (formerly UKCCSG)**

Kim S. Bull, Helen A. Spoudeas, Ghasem Yadegarfar, and Colin R. Kennedy 4239

BONE MARROW TRANSPLANTATION

- ① **Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation**

Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer, Michael B. Maris, Frédéric Baron, David G. Maloney, Bart L. Scott, H. Joachim Deeg, Frederick R. Appelbaum, and Rainer Storb 4246

Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease

David A. Jacobsohn, Allen R. Chen, Marianna Zahurak, Steven Piantadosi, Viki Anders, Javier Bolaños-Meade, Meghan Higman, Jeffrey Margolis, Michele Kaup, and Georgia B. Vogelsang 4255

Single Nucleotide Polymorphisms in the *NOD2/CARD15* Gene Are Associated With an Increased Risk of Relapse and Death for Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation With Unrelated Donors

Neema P. Mayor, Bronwen E. Shaw, Derralynn A. Hughes, Hazael Maldonado-Torres, J. Alejandro Madrigal, Satish Keshav, and Steven G.E. Marsh 4262

THORACIC ONCOLOGY

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

John V. Heymach, Bruce E. Johnson, Diane Prager, Edit Csada, Jaromír Roubec, Miloš Pešek, Irena Špásová, Chandra P. Belani, István Bodrogi, Shirish Gadgeel, Sarah J. Kennedy, Jeannie Hou, and Roy S. Herbst 4270

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

Andrew M. Arnold, Lesley Seymour, Michael Smylie, Keyue Ding, Yee Ung, Brian Findlay, Christopher W. Lee, Marina Djurfeldt, Marlo Whitehead, Peter Ellis, Glenwood Goss, Adrien Chan, Jacinta Meharchand, Yasmin Alam, Richard Gregg, Charles Butts, Peter Langmuir, and Frances Shepherd 4278

HEMATOLOGIC MALIGNANCIES

Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy

Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Stephen Revell, Katie Vo, and Arturo Molina 4285

Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Pier Luigi Zinzani, Gerardo Musuraca, Monica Tani, Vittorio Stefoni, Enrica Marchi, Mariapaola Fina, Cinzia Pellegrini, Lapo Alinari, Enrico Derenzini, Antonio de Vivo, Elena Sabattini, Stefano Pileri, and Michele Baccharani 4293

Biology of Neoplasia

Role of Lymphangiogenesis in Cancer

Sudha S. Sundar and Trivadi S. Ganesan 4298

Diagnosis in Oncology

Urinary Bladder Metastasis From Breast Cancer With Heterogeneous Expression of Estrogen and Progesterone Receptors

Wei-Ching Lin and Jeon-Hor Chen 4308

Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type Developing in Gonarthrosis Deformans

Jun-ichiro Ikeda, Eiichi Morii, Amane Yamauchi, Masaharu Kohara, Nobuyuki Hashimoto, Hideki Yoshikawa, Masafumi Iwasaki, and Katsuyuki Aozasa 4310

Lymphoplasmacytic Lymphoma Arising in the Setting of Hepatitis C and Mixed Cryoglobulinemia

Chandra Krishnan, John S. Cupp, Daniel A. Arber, and James D. Faix 4312

Correspondence

For Localized Gastroesophageal Cancer, You Give Chemoradiation Before Surgery, but Then What Happens?

Jaffer A. Ajani, Arlene M. Correa, Stephen G. Swisher, and Tsung-Teh Wu 4315

Expression Profiling in Breast Carcinoma: New Insights on Old Prognostic Factors?

Marc Debled, Gaëtan MacGrogan, Isabelle de Mascarel, Véronique Brouste, Hervé Bonnefoi, and Louis Mauriac 4316

In Reply

Sherene Loi, Benjamin Haibe-Kains, Christine Desmedt, and Christos Sotiriou 4317

Celecoxib Induces MRP-4 in Lung Cancer Cells: Therapeutic Implications

Angela Gradilone, Fabio Maria Pulcinelli, Lavinia Vittoria Lotti, Simone Martino, Teresa Mattiello, Luigi Frati, Anna Maria Aglianò, and Paola Gazzaniga 4318

In Reply

Rogerio C. Lilenbaum and Mark Socinski 4320

Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial?

Mario Mandalà, Cecilia Moro, Roberto Labianca, and Gianluigi Ferretti 4320a

In Reply

Malcolm J. Moore, Wendy Parulekar, and Keyue Ding 4321

Primary CNS Lymphomas Prognosis

Andrés J.M. Ferreri, Michele Reni, Emanuele Zucca, and Franco Cavalli 4322

In Reply

Lauren E. Abrey, Leah Ben-Porat, Katherine S. Panageas, Joachim Yahalom, Walter Curran, Christopher Schultz, Steven Leibel, Diana Nelson, Minesh Mehta, and Lisa M. DeAngelis 4324

Heat Shock Protein 70, Erythropoietin, and Cancer

Kurt C. Sizer 4326

In Reply

Michael Henke and Frank Pajonk 4326a

Docetaxel Plus Cyclophosphamide in Adjuvant Breast Cancer

Cristiano Ferrario and Lawrence C. Panasci 4327

In Reply

Stephen E. Jones 4327a

Erratum 4328

Also in This Issue

Information for Subscribers

Announcements

Information for Contributors

Manuscript Submission Checklist

Current Abstracts

Calendar of Oncology Events



Online supplementary information available at www.jco.org



Article was published online ahead of print at www.jco.org